Ketone esters spare muscle on semaglutide

A mouse study published in JCI Insight on 9 June 2026 reports that adding a ketone ester supplement to semaglutide treatment preserved skeletal muscle mass and function without reducing fat loss^[1]. The finding matters because up to 45% of weight lost on GLP-1 receptor agonists can come from lean tissue rather than fat. No approved countermeasure exists yet, and the question of how to preserve muscle during pharmacological weight loss is becoming one of the central open problems in obesity medicine.

What the study tested

Abuetabh et al. treated obese, glucose-intolerant mice with one of three regimens over three weeks: vehicle control, semaglutide alone, or semaglutide plus a beta-hydroxybutyrate-generating ketone ester. The team then measured body composition, grip strength, muscle endurance, and gene expression in skeletal muscle^[1].

Semaglutide monotherapy reduced lean mass, impaired muscle strength, and suppressed mitochondrial gene expression while elevating atrophy-related genes. When the ketone ester was added, those changes were prevented: the combination group kept its muscle mass and function while losing the same amount of fat as the semaglutide-only group.

The ketone ester used generates beta-hydroxybutyrate (BHB), the same ketone body the liver produces during extended fasting or ketogenic diets. By delivering BHB exogenously, the ester bypasses the need for dietary restriction while giving muscle cells an alternative fuel substrate.

Why muscle loss during GLP-1 therapy is a concern

Weight loss from any cause, whether calorie restriction, bariatric surgery, or pharmacotherapy, involves some lean tissue loss alongside fat. The question is proportion. The JCI Insight authors note that up to 45% of semaglutide-induced weight loss can be attributed to skeletal muscle^[1]. A 2026 network meta-analysis by Wachiraphansakul et al. in Diabetes, Obesity and Metabolism confirmed that several GLP-1 RAs, including semaglutide 1.0 mg weekly, significantly decreased lean mass from baseline^[2].

A separate expert review by Scheen (Expert Opinion on Drug Safety, 2026) concluded that the evidence remains mixed: some studies document excessive muscle loss, others report that muscle strength and function are not compromised. Scheen described the overall benefit-risk ratio of GLP-1 therapies as "positive in most patients" but called for more data in older and frail populations^[3].

The proposed mechanism

The researchers attribute semaglutide's muscle effect to mitochondrial dysfunction in skeletal muscle tissue. Semaglutide suppressed genes involved in mitochondrial energy production and upregulated genes associated with muscle atrophy. The ketone ester reversed both patterns^[1].

Think of it this way: semaglutide cuts calorie intake and shifts the body into a sustained energy deficit. Muscle tissue, which is metabolically expensive to maintain, gets downgraded when the energy supply drops. The ketone ester supplies an alternative fuel source directly to muscle mitochondria, allowing those cells to keep functioning normally even while fat stores are being burned off. The gene expression data supports this reading: the atrophy and mitochondrial shutdown signatures seen with semaglutide alone were absent in the combination group.

What we do not know yet

This is a three-week mouse study. Mice are not humans, three weeks is not a year of treatment, and the doses and metabolism differ between species. The authors themselves describe these as preclinical findings and call for clinical evaluation to assess translational potential.

Other lean-mass preservation strategies are also being studied. Arslan (Clinical Nutrition ESPEN, 2026) recommends protein intake of at least 1.2 g/kg daily (up to 1.6 g/kg), progressive resistance training, and structured micronutrient monitoring for patients on GLP-1 therapy^[4]. Whether ketone esters add anything beyond those established interventions in humans remains an open question.

There is also no data yet on whether ketone esters interact with semaglutide's metabolic benefits beyond weight and muscle. Effects on glycaemic control, cardiovascular risk markers, and long-term safety of combined use are all unstudied in this context. And the cost question is real: commercial ketone ester drinks currently run $30 to $50 per serving, which adds up quickly as a daily supplement alongside an already expensive medication.

Where this fits for readers

If you are on semaglutide or another GLP-1 receptor agonist such as tirzepatide and concerned about muscle loss, the current evidence-based recommendations remain resistance exercise and adequate protein intake. Ketone ester supplementation as a muscle-sparing add-on is, as of this writing, a preclinical hypothesis, not a clinical recommendation. Discuss any supplement changes with your prescriber.

We will update this article if and when human trial data on ketone esters plus GLP-1 receptor agonists becomes available. For broader context on how the GLP-1 drug class works, see our semaglutide overview and tirzepatide overview.